Digestive Diseases and Sciences

, Volume 55, Issue 8, pp 2123–2125 | Cite as

Serum Pepsinogens in Gastric Cancer Screening

  • Pelayo CorreaEmail author

Background and Significance

Approximately one million new cases of gastric cancer are expected in 2010 worldwide. This disease is the second most frequent cause of cancer deaths [1]. In most countries, the tumors are detected when the invasion of the muscularis propria has taken place and the prognosis is dismal, even after gastrectomy and chemotherapy, with 5-year survival rates around 20% [1]. If the tumors are diagnosed when limited to the mucosa and submucosa, so called “early” cancers, the 5-year survival rate is over 90% [2, 3]. In Japan, extensive screening programs taking advantage of abundant endoscopic resources and superb expertise, including the use of serum pepsinogen (PG) tests, have succeeded in diagnosing the majority of gastric cancers in their early stages [4]. Screening programs have led to an overall 5-year survival rate for gastric cancer in Japan of 40–60% [5]. Such resources are not available in most Western countries. In South Korea, with some of the highest...


Gastric Cancer Gastric Cancer Risk Serum Pepsinogen Gastric Corpus Gastric Cancer Screening 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Saka M, Katai H, Fukagawa T, Nijjar R, Sano T. Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer. 2008;11:214–218.CrossRefPubMedGoogle Scholar
  3. 3.
    Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–253.CrossRefPubMedGoogle Scholar
  4. 4.
    Miki K, Fujishiro M, Kodashima S, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc. 2009;21:78–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81:419–424.CrossRefPubMedGoogle Scholar
  6. 6.
    Kwak M-S, Kim N, Lee HS, Lee HE, Jung HC, Song IS. Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index. Dig Dis Sci. 2010. doi: 10.1007/s10620-010-1181-x.
  7. 7.
    Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982;83:204–209.PubMedGoogle Scholar
  9. 9.
    Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–143.CrossRefPubMedGoogle Scholar
  10. 10.
    Tava F, Luinetti O, Ghigna MR, et al. Type or extension of intestinal metaplasia and immature/atypical “indefinite-for-dysplasia” lesions as predictors of gastric neoplasia. Hum Pathol. 2006;37:1489–1497.CrossRefPubMedGoogle Scholar
  11. 11.
    Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004;11:141–147.CrossRefPubMedGoogle Scholar
  12. 12.
    Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the general population nutrition intervention trial cohort. Gut. 2009;58:636–642.CrossRefPubMedGoogle Scholar
  13. 13.
    Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol. 2008;43:1448–1455.CrossRefPubMedGoogle Scholar
  14. 14.
    Mizuno S, Kobayashi M, Tomita S, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer. 2009;12:158–163.CrossRefPubMedGoogle Scholar
  15. 15.
    Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci. 2010. doi: 10.1007/s10620-010-1154-0.
  16. 16.
    di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis. 2008;40:523–530.CrossRefPubMedGoogle Scholar
  17. 17.
    Con SA, Con-Wong R, Con-Chin GR, et al. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2007;16:2631–2636.CrossRefPubMedGoogle Scholar
  18. 18.
    Correa P, Piazuelo MB, Wilson K. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493–498.CrossRefPubMedGoogle Scholar
  19. 19.
    Meining A, Bayerdörffer E, Müller P, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998;432:311–314.CrossRefPubMedGoogle Scholar
  20. 20.
    Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst. 1970;44:297–306.PubMedGoogle Scholar
  21. 21.
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181.CrossRefPubMedGoogle Scholar
  22. 22.
    Varis K, Sipponen P, Laxen F, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki gastritis study group. Scand J Gastroenterol. 2000;35:950–956.CrossRefPubMedGoogle Scholar
  23. 23.
    Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol. 2006;163:629–637.CrossRefPubMedGoogle Scholar
  24. 24.
    Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci. 2009;54:2377–2384.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of MedicineVanderbilt University School of MedicineNashvilleUSA

Personalised recommendations